Phase I Study to Assess the Safety and Immunogenicity of an Intradermal COVID-19 DNA Vaccine Administered Using a Pyro-Drive Jet Injector in Healthy Adults.

Nakagami, Hironori; Hayashi, Hiroki; Sun, Jiao; Yanagida, Yuka; Otera, Takako; Nakagami, Futoshi; Hamaguchi, Shigeto; Yoshida, Hisao; Okuno, Hideo; Yoshida, Shota; Nakamaru, Ryo; Yokoyama, Serina; Fujimoto, Taku; Hongyo, Kazuhiro; Akeda, Yukihiro; Morishita, Ryuichi; Tomono, Kazunori; Rakugi, Hiromi

Nakagami, Hironori; Hayashi, Hiroki; Sun, Jiao; Yanagida, Yuka; Otera, Takako; Nakagami, Futoshi; Hamaguchi, Shigeto; Yoshida, Hisao; Okuno, Hideo; Yoshida, Shota; Nakamaru, Ryo; Yokoyama, Serina; Fujimoto, Taku; Hongyo, Kazuhiro; Akeda, Yukihiro; Morishita, Ryuichi; Tomono, Kazunori; Rakugi, Hiromi.

Afiliación

Nakagami H; Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Hayashi H; Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Sun J; Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Yanagida Y; Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Otera T; Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Nakagami F; Division of Infection Control and Prevention, Osaka University Hospital, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Hamaguchi S; Division of Infection Control and Prevention, Osaka University Hospital, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Yoshida H; Division of Infection Control and Prevention, Osaka University Hospital, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Okuno H; Division of Infection Control and Prevention, Osaka University Hospital, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Yoshida S; Department of Geriatric and General Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Nakamaru R; Department of Geriatric and General Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Yokoyama S; Department of Geriatric and General Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Fujimoto T; Department of Geriatric and General Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Hongyo K; Department of Geriatric and General Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Akeda Y; Division of Infection Control and Prevention, Osaka University Hospital, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Morishita R; Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Tomono K; Division of Infection Control and Prevention, Osaka University Hospital, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.
Rakugi H; Department of Geriatric and General Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.

Vaccines (Basel) ; 10(9)2022 Aug 30.

Article en En | MEDLINE | ID: mdl-36146505

Palabras clave

COVID-19; DNA vaccine; SARS-CoV-2

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Japón